Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.

Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.

Biocon eyes global insulin leadership as rivals pivot to GLP-1 therapies, betting on capacity gaps, pricing advantage and rising diabetes burden ...

Biocon chairperson Kiran Mazumdar-Shaw unveils corporate commute nudge under Toyota Mobility Foundation and WRI India’s STAMP ...

BENGALURU, India & BRIDGEWATER, N.J.-- (BUSINESS WIRE)--Apr 7, 2026-- ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's ...

At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...

Biocon chairperson Kiran Mazumdar-Shaw received assurance from Union Minister Nitin Gadkari that Hosur Road in Hebbagodi will ...